Statement Of Changes In Equity [Abstract]

Innate Pharma - Filing #882171

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	219 404 EUR	—	456,000 EUR	—	1 054 EUR	107 440 EUR	1 054 EUR	—	52 809 EUR	375 220 EUR	3 978 EUR	—	—	156 476 EUR	63 984 EUR	—	3 950 EUR	—	355,000 EUR	372 131 EUR	—	155 976 EUR	—	472,000 EUR	20 759 EUR	369 617 EUR	217 416 EUR	134 912 EUR	3 941 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	52 809 EUR	—	—	—	—	—	—	—	—	—	52 809 EUR	63 984 EUR	—	—	63 984 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	—	—	—	—	—	—	—	—	101,000 EUR	22,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive income	—	52 809 EUR	—	101,000 EUR	—	—	—	—	—	—	—	52 708 EUR	63 962 EUR	—	—	63 984 EUR	—	805,000 EUR	—	—	827,000 EUR	—	—	—	—	—	—	—	—
Issue of equity	—	—	—	—	—	—	—	—	—	—	—	— EUR	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	—	—	—	—	—	—	2 617 EUR	—	—	—	2 617 EUR	2 476 EUR	—	—	—	—	—	—	—	—	—	2 476 EUR	—	—	—	—	—	—